logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Promise without practice — charting the path forward for bladder cancer biomarkers

delete2025-07-02
delete0
PRE
AI
M
Marie-Pier St-Laurent *
P
Peter C. Black
DOI：10.1038/s41585-025-01064-0delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Bladder cancer is a biologically heterogeneous disease, and ongoing efforts in biomarker research aim to support personalized treatment approaches. Circulating tumour DNA is approaching clinical integration through prospective trials, whereas other markers remain investigational owing to technical limitations, inconsistent findings and lack of validation. Rigorous biomarker-driven trials and cost-effectiveness studies are needed to enable the integration of molecular tools into routine practice. Biomarkers might ultimately lead to rational treatment de-escalation or escalation, improving outcomes while minimizing harm and cost.

Journal

Nature Reviews Urology cover
Nature Reviews Urology
IF:
14.6
Papers:
2.3K
Citations:
7.5K

Organization

No organization information available